RNA-based therapeutic approaches for coagulation factor deficiencies.

Area of Science:

• Biochemistry
• Molecular Biology
• Genetics

Background:

• Substitutive therapy improves quality of life for patients with coagulation factor deficiencies but has limitations.
• Research is exploring alternative therapeutic strategies to overcome current treatment limitations.

Purpose of the Study:

• To investigate RNA-based strategies for rescuing coagulation factor biosynthesis by targeting RNA processing and translation.
• To restore altered gene expression while maintaining physiological tissue regulation.

Main Methods:

• Modification of U1 small nuclear RNA (snRNA) to correct splicing in the F7 gene.
• Spliceosome-mediated RNA trans-splicing (SMaRT) to produce normal FVIII mRNA.
• Aminoglycoside drugs to induce ribosome readthrough of premature translation termination in FVII, FVIII, and FIX genes.

Main Results:

• U1 snRNA modification led to correct mRNA synthesis and functional Factor VII secretion.
• SMaRT produced normal FVIII mRNA and functional protein secretion.
• Aminoglycosides induced ribosome readthrough, rescuing expression from very low to moderate levels.
• Rescued expression levels, though ranging from low to moderate, could ameliorate disease phenotypes.

Conclusions:

• RNA-based strategies demonstrate potential for treating coagulation factor deficiencies.
• Further studies are needed to confirm the clinical translatability of these RNA-based approaches.
• These findings open new therapeutic avenues for genetic bleeding disorders.